[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL3555097T3 - Związki imidazo[4,5-d]pirolo[2,3-b]pirydynowe jako inhibitory kinaz janusowych - Google Patents

Związki imidazo[4,5-d]pirolo[2,3-b]pirydynowe jako inhibitory kinaz janusowych

Info

Publication number
PL3555097T3
PL3555097T3 PL17854175.1T PL17854175T PL3555097T3 PL 3555097 T3 PL3555097 T3 PL 3555097T3 PL 17854175 T PL17854175 T PL 17854175T PL 3555097 T3 PL3555097 T3 PL 3555097T3
Authority
PL
Poland
Prior art keywords
pyrrolo
imidazo
inhibitors
pyridine compounds
janus kinases
Prior art date
Application number
PL17854175.1T
Other languages
English (en)
Inventor
Tatiana KOUDRIAKOVA
Kevin D. Kreutter
Kristi Leonard
Michele C. Rizzolio
Russell C. Smith
Mark S. Tichenor
Aihua Wang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PL3555097T3 publication Critical patent/PL3555097T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL17854175.1T 2016-12-16 2017-12-15 Związki imidazo[4,5-d]pirolo[2,3-b]pirydynowe jako inhibitory kinaz janusowych PL3555097T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662435609P 2016-12-16 2016-12-16
US201762592680P 2017-11-30 2017-11-30
US201762596607P 2017-12-08 2017-12-08
PCT/US2017/066744 WO2018112379A1 (en) 2016-12-16 2017-12-15 Small molecule inhibitors of the jak family of kinases

Publications (1)

Publication Number Publication Date
PL3555097T3 true PL3555097T3 (pl) 2022-10-17

Family

ID=61692222

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17854175.1T PL3555097T3 (pl) 2016-12-16 2017-12-15 Związki imidazo[4,5-d]pirolo[2,3-b]pirydynowe jako inhibitory kinaz janusowych

Country Status (35)

Country Link
US (5) US10294226B2 (pl)
EP (2) EP3555097B1 (pl)
JP (2) JP7291077B2 (pl)
KR (1) KR102352462B1 (pl)
CN (1) CN110088105B (pl)
AU (3) AU2017377069B2 (pl)
CA (1) CA3046965A1 (pl)
CL (1) CL2019001626A1 (pl)
CO (1) CO2019006200A2 (pl)
CR (1) CR20190282A (pl)
DK (1) DK3555097T3 (pl)
EC (1) ECSP19042688A (pl)
ES (1) ES2922379T3 (pl)
HR (1) HRP20220885T1 (pl)
HU (1) HUE059274T2 (pl)
IL (1) IL267275B (pl)
JO (1) JOP20190143B1 (pl)
LT (1) LT3555097T (pl)
MD (1) MD3555097T2 (pl)
MX (2) MX2019007073A (pl)
MY (1) MY196260A (pl)
NI (1) NI201900060A (pl)
NZ (1) NZ755404A (pl)
PE (1) PE20191105A1 (pl)
PH (1) PH12019501254A1 (pl)
PL (1) PL3555097T3 (pl)
PT (1) PT3555097T (pl)
RS (1) RS63500B1 (pl)
SA (1) SA519402216B1 (pl)
SI (1) SI3555097T1 (pl)
SM (1) SMT202200326T1 (pl)
TW (1) TWI777997B (pl)
UA (1) UA125042C2 (pl)
WO (1) WO2018112379A1 (pl)
ZA (1) ZA201904615B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20191078A1 (es) 2016-10-24 2019-08-20 Astrazeneca Ab Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina utiles en el tratamiento del cancer
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
ES2922379T3 (es) 2016-12-16 2022-09-14 Janssen Pharmaceutica Nv Compuestos de imidazo[4,5,D]pirrolo[2,3,B]piridina como inhibidores de Janus quinasas
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物
MX2019008438A (es) 2017-01-30 2019-10-30 Astrazeneca Ab Moduladores del receptor de estrogeno.
TW202016110A (zh) * 2018-06-15 2020-05-01 比利時商健生藥品公司 Jak激酶家族之小分子抑制劑
CN112654610B (zh) 2018-06-15 2024-12-24 里亚塔医药公司 用于抑制IL-17和RORγ的吡唑和咪唑化合物
US12060340B2 (en) 2018-06-20 2024-08-13 Reata Pharmaceuticals, Inc Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith
US20200338051A1 (en) 2019-04-24 2020-10-29 Janssen Pharmaceutica Nv Non-clinical liquid formulations of pan-jak inhibitor
CA3142625A1 (en) 2019-06-06 2020-12-10 Highlightll Pharmaceutical (Hainan) Co., Ltd Synthesis method of furoimidazopyridine compound, crystal form of furoimidazopyridine compound, and crystal form of salt thereof
CN110483514B (zh) * 2019-09-16 2022-06-14 启元生物(杭州)有限公司 一种氰基取代的环肼衍生物及其应用
CN115038701B (zh) * 2020-02-21 2023-06-16 珠海联邦制药股份有限公司 Jak抑制剂的晶型及其应用
CN114149428B (zh) * 2020-09-08 2023-06-13 中国药科大学 吡啶并环类化合物及其制备方法、中间体、组合物和应用
US20220288041A1 (en) 2021-03-11 2022-09-15 Janssen Pharmaceutica Nv Small molecule inhibitor of the jak family of kinases
CN113292561A (zh) * 2021-05-22 2021-08-24 中国药科大学 一种二吡咯并吡啶结构的化合物、制备方法和医药用途
CN114432317A (zh) * 2021-05-31 2022-05-06 广州嘉越医药科技有限公司 吡咯并嘧啶类化合物的用途
CN113861194B (zh) * 2021-11-10 2022-07-05 英维沃化工科技(广州)有限公司 一种含吡咯并吡啶双酰胺咪唑类化合物及其制备方法和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
CN1167702C (zh) 1999-04-23 2004-09-22 史密丝克莱恩比彻姆有限公司 5-[4-[2-n-甲基-n-(2-吡啶基)氨基]乙氧基]苄基]噻唑烷-2,4-二酮马来酸盐的多晶型物
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
DE60319980T2 (de) 2002-05-31 2009-04-16 Schering Corporation Xanthin-phosphodiesterase-v-hemmer polymorphe
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
US7737279B2 (en) 2005-05-10 2010-06-15 Bristol-Myers Squibb Company 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
MX2008000384A (es) 2005-07-01 2008-03-07 Wyeth Corp Formas cristalinas de 4-[(2,4-dicloro-5-metoxifenil)amino]-6-metox i-7-[3-(4-metil-1-piperazinil)propoxi]-3-quinolinocarbonitrilo y metodos para su preparacion.
KR20080026654A (ko) * 2005-07-14 2008-03-25 아스텔라스세이야쿠 가부시키가이샤 헤테로시클릭 야누스 키나제 3 억제제
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
JP5748659B2 (ja) 2008-06-10 2015-07-15 アッヴィ・インコーポレイテッド 新規な三環式化合物
PE20121150A1 (es) 2009-09-03 2012-08-27 Bristol Myers Squibb Co Inhibidores de jak2 y su uso en el tratamiento de enfermedades mieloproliferativas y cancer
JP2011066747A (ja) * 2009-09-18 2011-03-31 Panasonic Corp 弾性波フィルタ
US8785639B2 (en) 2009-12-01 2014-07-22 Abbvie Inc. Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof
RS56317B1 (sr) 2009-12-01 2017-12-29 Abbvie Inc Nova triciklična jedinjenja
JP2013517220A (ja) 2010-01-12 2013-05-16 エフ.ホフマン−ラ ロシュ アーゲー 三環式複素環式化合物、その組成物、及び使用の方法
EP2534258B1 (en) 2010-02-10 2017-09-20 Genon Biotechnologies OY Dual activity kinase domains and uses thereof
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
EP2955181B1 (en) 2013-02-08 2019-10-30 Nissan Chemical Corporation Tricyclic pyrrolopyridine compound, and jak inhibitor
EP2924026A1 (en) * 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
RU2674262C2 (ru) 2014-05-14 2018-12-06 Ниссан Кемикал Индастриз, Лтд. Трициклическое соединение и ингибитор jak
EP3303348B1 (en) 2015-05-28 2019-08-07 Theravance Biopharma R&D IP, LLC Naphthyridine compounds as jak kinase inhibitors
WO2017079639A1 (en) 2015-11-04 2017-05-11 Mayo Foundation For Medical Education And Research Methods and materials for treating autoimmune conditions
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
PE20191078A1 (es) 2016-10-24 2019-08-20 Astrazeneca Ab Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina utiles en el tratamiento del cancer
UA122035C2 (uk) 2016-12-16 2020-08-25 Пфайзер Інк. Агоністи рецептора glp-1 та їх застосування
JP2020502117A (ja) 2016-12-16 2020-01-23 ビーエーエスエフ ソシエタス・ヨーロピアBasf Se 殺生物剤化合物
ES2922379T3 (es) 2016-12-16 2022-09-14 Janssen Pharmaceutica Nv Compuestos de imidazo[4,5,D]pirrolo[2,3,B]piridina como inhibidores de Janus quinasas
NZ754115A (en) 2016-12-16 2021-07-30 Lilly Co Eli 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
MX2019006047A (es) 2016-12-16 2019-10-02 Nestle Sa Oligosacaridos para generacion de sabor.
LT3568396T (lt) 2017-01-11 2021-02-10 Leo Pharma A/S Nauji amino-imidazopiridino dariniai, kaip janus kinazės inhibitoriai ir jų farmacinis panaudojimas
MX2019008438A (es) 2017-01-30 2019-10-30 Astrazeneca Ab Moduladores del receptor de estrogeno.
EP3612030A4 (en) 2017-04-21 2021-04-28 Ikena Oncology, Inc. AHR INDOLE INHIBITORS AND THEIR USES
CN106881892B (zh) 2017-04-27 2020-10-16 双钱集团(江苏)轮胎有限公司 一种轮胎生产用生胎转移系统
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Jak激酶家族之小分子抑制劑
US20200338051A1 (en) 2019-04-24 2020-10-29 Janssen Pharmaceutica Nv Non-clinical liquid formulations of pan-jak inhibitor

Also Published As

Publication number Publication date
AU2017377069A1 (en) 2019-06-20
ES2922379T3 (es) 2022-09-14
US10487083B2 (en) 2019-11-26
IL267275A (en) 2019-08-29
CL2019001626A1 (es) 2019-10-04
US20210340143A1 (en) 2021-11-04
AU2017377069B2 (en) 2020-07-23
EP4086256A1 (en) 2022-11-09
CA3046965A1 (en) 2018-06-21
JOP20190143B1 (ar) 2023-09-17
UA125042C2 (uk) 2021-12-29
JP2020502113A (ja) 2020-01-23
DK3555097T3 (da) 2022-07-25
PT3555097T (pt) 2022-09-22
SI3555097T1 (sl) 2022-09-30
PE20191105A1 (es) 2019-08-23
KR20190086779A (ko) 2019-07-23
IL267275B (en) 2021-07-29
US20180170931A1 (en) 2018-06-21
HUE059274T2 (hu) 2022-11-28
HRP20220885T1 (hr) 2022-12-09
SA519402216B1 (ar) 2022-10-02
JP7493068B2 (ja) 2024-05-30
EP3555097B1 (en) 2022-06-15
LT3555097T (lt) 2022-08-25
JP2023071709A (ja) 2023-05-23
MY196260A (en) 2023-03-24
MX2019007073A (es) 2019-10-15
NI201900060A (es) 2020-03-16
SMT202200326T1 (it) 2022-09-14
AU2020257068A1 (en) 2020-11-19
BR112019011968A2 (pt) 2019-11-05
JOP20190143A1 (ar) 2019-06-13
US10294226B2 (en) 2019-05-21
CR20190282A (es) 2019-08-21
AU2022204240A1 (en) 2022-07-07
JP7291077B2 (ja) 2023-06-14
RS63500B1 (sr) 2022-09-30
US12202831B2 (en) 2025-01-21
US11059823B2 (en) 2021-07-13
WO2018112379A1 (en) 2018-06-21
AU2022204240B2 (en) 2023-10-05
US20190177322A1 (en) 2019-06-13
PH12019501254A1 (en) 2020-01-20
NZ755404A (en) 2024-10-25
CN110088105A (zh) 2019-08-02
MX2022004474A (es) 2023-08-15
US20190177321A1 (en) 2019-06-13
ZA201904615B (en) 2021-05-26
CO2019006200A2 (es) 2019-06-28
TW201831180A (zh) 2018-09-01
US20190185474A1 (en) 2019-06-20
TWI777997B (zh) 2022-09-21
US10364246B2 (en) 2019-07-30
ECSP19042688A (es) 2019-06-30
MD3555097T2 (ro) 2022-12-31
CN110088105B (zh) 2022-03-18
KR102352462B1 (ko) 2022-01-17
EP3555097A1 (en) 2019-10-23

Similar Documents

Publication Publication Date Title
SMT202200326T1 (it) Composti imidazo[4,5-d]pirrolo[2,3-b]piridinici come inibitori di chinasi janus
IL277576A (en) Mutated pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
HUS2200003I1 (hu) Pirrolo [2,3-D]pirimidin származékok mint a Janus-kinázok (JAK) inhibitorai
IL265918A (en) Pyrazolo [1,5– A] compounds Pyridine is converted as RET kinase inhibitors
HK1258905A1 (zh) 作為ret激酶抑制劑的取代的吡唑並[1,5-a]吡啶化合物
HK1248675A1 (zh) 調節激酶的1h 吡咯並[2,3-b]吡啶衍生物的合成
IL266305B (en) History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors
PT3712152T (pt) Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase
PT3371185T (pt) Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase
IL266986B (en) Imidazo[1,5-a]pyrazine derivatives as inhibitors of pi3k delta
EP3856743A4 (en) SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS